[Not Available].

Breast cancer is the most commonly occurring form of cancer in pregnancy. Among women aged between 25 and 29 years, one in five cases of breast cancer will occur in pregnancy or during the first postnatal year. The prevalence is increasing, presumably because of the increase in maternal age at pregnancy.

Young adolescent boys' and girls' attitudes toward uncommitted sexual behaviors and the perception of interest in sexual exploration in opposite-gender relations.

The aim of this study is to measure young adolescent boys' and girls' attitudes toward uncommitted sexual behaviors and gain insight into their perception of peers' sexual exploration interest in committed versus non-committed opposite-gender relations. We constructed a new 5-item measurement of young adolescents' attitudes toward uncommitted sexual behavior (sociosexuality) and report on the reliability and construct validity of the scale. Analyses were performed on a sample of 425 secondary school students (187 boys, 238 girls, Mean age = 14.

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.

Purpose: We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor-positive breast cancer (BC) desiring future pregnancy.

Patients And Methods: POSITIVE is an international, single-arm, prospective trial, in which 518 women temporarily interrupted adjuvant endocrine therapy to attempt pregnancy. We evaluated menstruation recovery and factors associated with time to pregnancy and investigated if ART use was associated with achieving pregnancy.

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.

Background: Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking.

Methods: We conducted a single-group trial in which we evaluated the temporary interruption of adjuvant endocrine therapy to attempt pregnancy in young women with previous breast cancer. Eligible women were 42 years of age or younger; had had stage I, II, or III disease; had received adjuvant endocrine therapy for 18 to 30 months; and desired pregnancy.

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.

Background: Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5-10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact of temporary ET interruption to allow pregnancy.

Methods: POSITIVE enrolled women with stage I-III HR + early breast cancer, ≤42 years, who had received 18-30 months of adjuvant ET and wished to interrupt ET for pregnancy.